Increased immunoreactivities against endothelin-converting enzyme-1 and monocyte chemotactic protein-1 in hepatic stellate cells of rat fibrous liver induced by thioacetamide

• Published in: Medical molecular morphology 2005-09, Vol.38 (3), p.161-172
• Main Authors: Nagata, Takahisa, Kudo, Hideaki, Nishino, Tomoko, Doi, Yoshiaki, Itoh, Hideaki, Fujimoto, Sunao
• Format: Article
• Language: English
• Subjects: Actin; Animals; Antibodies; Aspartic Acid Endopeptidases - analysis; Chemokine CCL2 - analysis; Endothelin-Converting Enzymes; Enzymes; Fibrosis; Fibrosis - chemically induced; Immunocytochemistry; Immunohistochemistry; Immunoreactivity; Liver; Liver - chemistry; Liver - cytology; Liver - drug effects; Liver - pathology; Male; Metalloendopeptidases - analysis; Microscopy, Immunoelectron; Monocyte chemoattractant protein 1; Muscles; Rats; Rats, Wistar; stellate cells; Thioacetamide; Thioacetamide - toxicity
• ISSN: 1860-1480; 1860-1499
• DOI: 10.1007/s00795-005-0292-5

The progression of rat liver fibrosis induced by intraperitoneal administration of thioacetamide (TAA) was evaluated by immunocytochemistry using anti-alpha-smooth muscle actin (alpha-SMA), antiendothelin-converting enzyme (ECE)-1, and anti-monocyte chemotactic protein (MCP)-1 antibodies. The fibrous septal spaces gradually increased after administration of TAA, and pseudolobules were established in the 7-week TAA-treated groups. Immunoreactivities against alpha-SMA were not detected in hepatic stellate cells (HSCs) of the control group without TAA treatment, although they were observed in the HSCs around the fibrous septal spaces in all TAA-treated groups, indicating that activation of HSCs occurs during the establishment of pseudolobules. Immunoreactivities against ECE-1 and MCP-1 were seen in such HSCs of the TAA-treated groups, but few or no immunoreactivities were detected in the HSCs of the control group. The most significant increase in the ECE-1 immunoreactivities was detected in the 1-week TAA-treated group, whereas that in MCP-1 was observed in the 7-week TAA-treated group. The present immunocytochemistry indicated a difference in the accelerated expression period between immunoreactivities against ECE-1 and MCP-1 in the HSCs during the progression of TAA-induced liver fibrosis, suggesting that ECE-1 is involved in the early phase of liver fibrosis and that MCP-1 plays a role during the later phase.